The research takes place within the collaboration framework between the Center for Molecular Immunology of Cuba and the Roswell Park Center of the United States.
collaborative study between researchers from the Roswell Park Comprehensive Cancer Center, in the United States, and the Center for Molecular Immunology (CIM), in Cuba, revealed a new strategy to correct immune dysfunction in cancer patients.
This research takes place within the collaboration framework between Roswell Park and the CIM, materialized in the joint venture Innovative Immunotherapy Alliance (IIA), located in the Mariel Special Development Zone.
According to a publication on the Roswell Park website, from a paper published in the Journal for ImmunoTherapy of Cancer, the findings of this research, which involved both laboratory studies and an early phase clinical trial, show that a new immune modulator, known as VSSP (very small particle size), developed by the CIM, can significantly reduce myeloid-derived suppressor cells (MDSC), in people with advanced kidney cancer.
This work, he noted, opens the door for the development of an immunomodulatory therapy that could overcome immune dysfunction, which in this case is an overproduction of MDSCs that can aid cancer progression by creating more favorable conditions for generating an antitumor response.
“While it is appreciated that the immune system can be effective against cancer, we also know that the effectiveness of existing therapies can be hampered by counter networks of immune suppression,” said Scott Abrams, senior author of the new work.
The researchers sought an alternative method to target MDSCs using VSSP, which has been in clinical development in Cuba for more than ten years, and has been incorporated into the formulation of three candidate cancer vaccines currently in various stages of clinical testing, including Phase III trials. (National News Office)
Translated y ESTI